Rising Unmet Medical Needs and Growing Prevalence of Skin Diseases is Augmenting the Demand for Pruritus Therapeutics
The growth of the market is majorly driven by the growing prevalence of health conditions mentioned above associated with pruritus. The rising unmet medical needs and the introduction of various innovative products to treat the conditions are driving the growth of the Pruritus Therapeutics Market. The rising incidences of atopic dermatitis and the development of promising and robust pipeline therapeutics are anticipated to propel the market’s growth over the coming years. Corticosteroids are the most commonly used therapeutics to treat skin conditions owing to their efficiency in reducing inflammation. This is driving the need for over-the-counter corticosteroids, thereby contributing to the pruritus therapeutics market’s growth. With a rising pruritus patient pool and untapped potential for business expansion in countries like India and China, the pruritus therapeutics market is expected to grow significantly in the Asia Pacific.
In October 2020, Cara Therapeutics and Vifor Pharma
signed a license agreement for the commercialization of Korsuva Injection to
treat chronic kidney disease-associated pruritus in patients on dialysis in the
United States. In October 2020, Titan Pharmaceuticals and JT Pharmaceuticals
signed a definitive asset purchase agreement to acquire the latter’s kappa
opioid agonist peptide, JT-09, for the treatment of chronic pruritus.
Read full press release at: https://www.reportsanddata.com/press-release/global-pruritus-therapeutics-market
Comments
Post a Comment